Stock Price Quote

HINDUSTAN BIO SCIENCES LTD.

NSE : NABSE : 532041ISIN CODE : INE597C01021Industry : Pharmaceuticals & DrugsHouse : Private
BSE8.100 (0 %)
PREV CLOSE ( ) 8.10
OPEN PRICE ( ) 8.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6584
TODAY'S LOW / HIGH ( )8.00 8.49
52 WK LOW / HIGH ( ) 5.1515.18
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1991
Management Info
J V R Mohan Raju - Chairman J V R Mohan Raju - Managing Director
Registered Office

Address H No.8-2-269/ S, Plot No 31 ,Sagar Co-operative Housing Society ,Road No 2, Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040- 23555161

Email info@hindustanbiosciences.in

Website https://www.hindustanbiosciences.in/

Registrars Details
Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE

NEWS

10Mar Hindustan Bio Sciences informs about o
Hindustan Bio Sciences has informed that the Board of Directors of the c..
28Dec Hindustan Bio Sciences informs about o
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Dis..
04Jun Hindustan Biosciences informs about re
Hindustan Biosciences has informed that it enclosed copy of the revised..
18Apr Hindustan Bio Sciences informs about c
In accordance with Regulation 74 (5) of the SEBI (Depositories and Parti..
24Jan Hindustan Biosciences informs about bo
Hindustan Biosciences has informed the exchange that meeting of the Boar..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit0.7-0.399999999999999
Gross Profit 0.7 -0.379999999999999
Operating Profit 0.72-0.279999999999999
Net Sales 3.229.22

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

NON-INSTITUTION 87.81%
PROMOTERS 12.19%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Hindustan Bio Sciences Ltd.

Hindustan Bio Sciences Ltd. was incorporated in the year 1991. Its today's share price is 8.1. Its current market capitalisation stands at Rs 8.3 Cr. In the latest quarter, company has reported Gross Sales of Rs. 9.22 Cr and Total Income of Rs.9.22 Cr. The company's management includes Reji Abraham, Jaison George, Sukavasi Jyotsna, M Satyanarayana Raju, K Rama Chandra Raju, B R Rao, J Uma, J V R Mohan Raju, J V R Mohan Raju.

It is listed on the BSE with a BSE Code of 532041 , NSE with an NSE Symbol of and ISIN of INE597C01021. It's Registered office is at H No.8-2-269/ S, Plot No 31 ,Sagar Co-operative Housing Society ,Road No 2, Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are C Ramachandam & Co, C Ramachandram & Co, VASG & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.